You are here :

  1. Home

Change language :

Français

Menu outils :

  1. Contact |
  2. Glossary |
  3. Help |
  4. Legal notice |
  5. RSS |
  6. Add this page to your favorite

    Cette fonctionnalit est en javascript mais peut tre aussi effectu comme suit : aller dans le menu favoris, puis ajouter aux favoris

The information provided in this site is intended only for media, financial analysts and healthcare professionals.

 

Thrombosis: disease prevention & treatment, safety first

Press release

August 26, 2010

Thromboembolism LMWHs Enoxaparin Biological Academic

Thromboembolism

Thromboembolism claims annually more lives than Breast Cancer and car accident together. It's a major public health issue affecting frail populations.

Thromboembolism

Low Molecular Weight Heparins

[LMW] Heparins are complex polysaccharide mixtures with specific benefit-risk profiles defined in clinical trials. LMWHs are not interchangeable.

Enoxaparin

Enoxaparin exclusive structure and positive benefit-safety balance depend on a proprietary manufacturing and rely on a 200 millions real life prescriptions.

Biological

Biological nature of exoxaparin relies on multi-system quality assurance. Its process prevents contamination risk and ensures complete traceability.

Academic

Academic organisations have examined the available scientific evidence and expressed their opinions over extrapolating data to other similar compounds of the same class.

Interview of Pr Job Harenberg

Editorial by Pr Lord A. Kakkar from Barts and the London-Queen Mary School of Medicine, London

Video testimonial from Pr Lord A. Kakkar